4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Ardelyx, Inc. (ARDX) operates in the Biotechnology industry and is headquartered in Waltham, United States with about 489 employees. Its market capitalization is roughly $1 billion. In the fiscal year ended 2025-12-31, ARDX reported $407M in revenue and ($62M) in net income.
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
Interactive charts & full statements → Open the ARDX valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $407M | $334M | $124M | $52M | — |
| Gross Profit | $368M | $283M | $107M | $48M | — |
| Operating Income (EBIT) | ($41M) | ($28M) | ($63M) | ($64M) | — |
| Net Income | ($62M) | ($39M) | ($66M) | ($67M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $94M | $125M | $110M | $98M | $74M |
| Gross Profit | $90M | $114M | $106M | $85M | $62M |
| Operating Income (EBIT) | ($33M) | $5M | $5M | ($14M) | ($36M) |
| Net Income | ($38M) | ($0M) | ($1M) | ($19M) | ($41M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $502M | $436M | $298M | $190M | — |
| Total Liabilities | $335M | $262M | $131M | $92M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ARDX viewer.
About TickerBase · Data methodology & sources